Research & Markets: Only Eli Lilly's Symbyax and AstraZeneca's Seroquel have Received FDA Approval for Treatment of Bipolar Depression.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c53479) has announced the addition of the Decision Resources, Inc report: Bipolar Disorder bipolar disorder, formerly manic-depressive disorder or manic-depression, severe mental disorder involving manic episodes that are usually accompanied by episodes of depression. : Can Competitive Advantage Be Established in a Challenging Market? to their offering. A poorly understood, complex disease that involves a number of neurotransmitters Neurotransmitters Chemicals within the nervous system that transmit information from or between nerve cells. Mentioned in: Bulimia Nervosa, Impotence, Pain, Withdrawal Syndromes , bipolar disorder presents several challenges for pharmaceutical companies seeking to develop new treatments. While lithium and several antiepileptic and antipsychotic agents are currently used to treat either manic or mixed episodes of BPD, only Eli Lilly's Symbyax and AstraZeneca's Seroquel have received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for treatment of bipolar depression. The numerous unmet therapeutic needs resulting from the incomplete understanding of BPD create significant opportunities within the competitive BPD market. Get the Answers You Need to Shape Your Strategy Bipolar disorder represents a market with significant opportunity, but few drug companies are actively developing new agents. What obstacles are currently deterring companies from entering the BPD market? What challenges need to be addressed, and what therapeutic needs remain unmet? The treatment of depression associated with BPD has not been as extensively studied as the treatment of either unipolar unipolar /uni·po·lar/ (u?ni-po´ler) 1. having a single pole or process, as a nerve cell. 2. pertaining to mood disorders in which only depressive episodes occur. depression or bipolar mania. What strategies does treatment of bipolar depression rely upon? Which classes of antidepressants Antidepressants Medications prescribed to relieve major depression. Classes of antidepressants include selective serotonin reuptake inhibitors (fluoxetine/Prozac, sertraline/Zoloft), tricyclics (amitriptyline/ Elavil), MAOIs (phenelzine/Nardil), and heterocyclics appear to be the most effective for treating bipolar depression? Several agents have received specific approval for treating BPD; other agents are commonly used off-label. Which agents are most frequently used as off-label treatments for BPD? What competitive advantages, if any, does FDA approval provide? Which companies are specifically pursuing FDA approval for their BPD agents? Scope -- BPD background: Symptoms, pathophysiology pathophysiology /patho·phys·i·ol·o·gy/ (-fiz?e-ol´ah-je) the physiology of disordered function. path·o·phys·i·ol·o·gy n. 1. , and etiology. -- Treatment options: Current therapies for the four common types of episodes associated with bipolar I Bipolar I is a sub-diagnosis of bipolar disorder. Diagnosis of Bipolar I requires at least one Manic or Mixed episode, but there may be episodes of Hypomania or Major Depression as well. (This diagnosis conforms to the classic concept of manic depressive illness. disorder and bipolar II bipolar II n. See dysphoric hypomania. disorder. -- Market dynamics: Sales growth statistics for BPD-approved agents versus non-BPD-approved agents; sales and prescriptions of antipsychotics Antipsychotics A class of drugs used to control psychotic symptoms in patients with psychotic disorders such as schizophrenia and delusional disorder. Antipsychotics include risperidone (Risperdal), haloperidol (Haldol), and chlorpromazine (Thorazine). and antiepileptics in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . -- Emerging therapies: Antipsychotics and sodium- and calcium-channel blockers currently in development, along with novel approaches. -- Market outlook: Limitations of current BPD agents; challenges still remaining; and the likelihood that any one agent will dominate the BPD market. Topics Covered Executive Summary Strategic Considerations Stakeholder Implications Introduction Overview of Bipolar Disorder Symptoms, Pathophysiology, and Etiology Types of Bipolar Disorder Diagnosis, Epidemiology, and Impact of Bipolar Disorder Current Pharmacological Therapies for Bipolar Disorder Lithium Antiepileptic Agents Antipsychotic Agents Antidepressants Does Approval Aid Adoption? Emerging Therapies for Treatment of Bipolar Disorder
Bipolar disorder has not currently been cured but it can be managed. Emerging Antipsychotic Agents Janssen's Invega Extended-Release Tablets Organon's Asenapine Solvay's/Wyeth's/Lundbeck's Bifeprunox Vanda Pharmaceuticals' Iloperidone Sodium- and Calcium-Channel Modulators in Development for Bipolar Disorder Novartis's Licarbazepine (LIC-477) Memory Pharmaceuticals' MEM-1003 Novel Approaches to the Treatment of Bipolar Disorder Outlook for the Bipolar Disorder Market Tables: 1. Agents Commonly Used to Treat Bipolar Disorder, 2006 2. Emerging Agents for the Treatment of Bipolar Disorder 3. Sales of Leading Agents to Treat Bipolar Disorder, 2006 Figures: 1. Prevalent Cases of Bipolar Disorder by Type in the Major Markets, 2006 2. U.S. Sales of Antipsychotics Used in the Treatment of Bipolar Disorder 3. U.S. Prescriptions of Antipsychotics Used in the Treatment of Bipolar Disorder 4. U.S. Sales of Antiepileptics Used in the Treatment of Bipolar Disorder 5. U.S. Prescriptions of Antiepileptics Used in the Treatment of Bipolar Disorder 6. Regional Shares of Bipolar Disorder Treatment Sales in the Major Markets, 2006 Companies Mentioned - Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. - AstraZeneca - Bristol-Myers Squibb - Dainippon - D-Pharm - Eli Lilly - Forest Laboratories - Gedeon Richter - GlaxoSmithKline - Hoechst Marion Roussel - Janssen - Janssen-Cilag International - Johnson & Johnson - Kyowa Hakko - H. Lundbeck - Marinus Pharmaceuticals - McNeil - Memory Pharmaceuticals - Novartis - Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. - Ortho-McNeil - Otsuka Pharmaceutical - Pfizer - Repligen - Sanofi -Aventis - Shire Pharmaceutical - Solvay Pharmaceuticals - Taisho - Titan Pharmaceuticals - Vanda Pharmaceuticals - Wyeth For more information visit http://www.researchandmarkets.com/reports/c53479. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion